• The study included a 12-month retrospective medical record abstraction, a cross-sectional patient reported outcomes survey, and a 7-day prospective patient diary to evaluate symptoms and productivity
Data Sources
• Medical resource utilization data associated with CSU were collected from retrospective medical records (previous 12 months before inclusion) and patient surveys (previous 3 months)
• Medical charts data included therapies for CSU health care professional visits (e.g., routine general dermatologist, primary care general practitioner), hospital visits, emergency room (ER) visits and laboratory tests (e.g., full blood count with differential, sedimentation rate)
• Health-related resource use from the patient survey included patient-reported alternative medicine visits (e.g., acupuncture, naturopath), transportation (e.g., ambulance transportation), and other out-of-pocket expenses from the past 3 months
• Country-level unit costs were obtained from national sources for 2014 and reported in the respective local currencies
Statistical Analysis
• For each country, direct costs were calculated by applying unit costs to each resource • Total Direct Costs from the chart data from the previous 12 months were reported as mean (SD) • Total Other Direct Costs from the patient survey from the previous 3 months were annualised to generate other direct costs during a 12-month period and reported as mean (SD) • To enable comparison across countries, the purchasing power parity (PPP) approach was used. The PPP approach allows the exchange rate be equal to the purchasing power of each country's currency 7, 8 • PPP exchange rates help to minimize misleading international comparisons that can arise with the use of market exchange rates
• Each month, the Organisation for Economic Cooperation and Development (OECD) measures the difference in price levels between its member countries by calculating the ratios of PPPs for private final consumption expenditure to exchange rates 7 • Mean (SD) country costs were divided by the corresponding PPP exchange rate published by the OECD for 2014 ( Figure 1) • The mean (SD) annual total direct costs for each country in the respective country currencies are presented in Table 2 (Figure 1) • Overall, annual total direct costs were notably higher in France, due to therapy cost of intravenous immunoglobulin use and higher inpatient costs • The mean (SD) total other direct costs for each country are presented in Table 3 • Mean (SD) annual total other direct costs from the patient survey ranged from PPP$199.1 (419.6) in Spain to PPP$960.0 (1444.2) in Canada (Figure 2) • Alternative medicine visits contributed to higher other direct costs in Canada; where 16% of patients reported alternative medicine visits, with one patient reporting 15 alternative medicine visits during the previous 3 months 
CONCLUSIONS
• The current study found that CSU is associated with substantial direct healthcare costs across countries • The higher than expected costs associated with CSU suggest the need for effective treatment among the inadequately-controlled CSU patient population
